We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Gene Logic Releases ASCENTA® System 2.0

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Gene Logic Inc. has announced the release of ASCENTA® System 2.0, a version of its existing web-based product for gene and biomarker discovery and validation.

Version 2.0 is designed to offer gene expression information and progressive tools to help researchers identify key genes and biological pathways which possess distinctive expression characteristics and disease-related expression patterns.

The ASCENTA System includes Gene Logic's marker/X™ Tool, pathwayPrioritizer™ Tool, Diff/X™ Summary Tables and human gene expression information, including inflammation content for multiple sclerosis and inflammatory bowel disease, and central nervous system content for Parkinson's disease.

Dennis Rossi, senior vice president and general manager, Genomics for Gene Logic, said, “The ASCENTA System 2.0 provides our customers with a suite of new tools and functionalities that are unique in the marketplace.”

“This new version is a necessary evolution to meet the complex and changing needs of our customers.”

“Our goal is to furnish our customers with new tools to better understand the regulation of key biological pathways in human disease and quickly identify genes with unique and distinguishing expression patterns in human tissues.”

“We envision that dynamic application of these new tools to our enhanced gene expression data will quicken the path to drug target, biomarker and pathway discovery.”